Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma: Net profit leapfrogs 50% - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 19, 2001

    Sun Pharma: Net profit leapfrogs 50%

    Sun Pharmaceuticals has posted a growth of 50% in net profit for 2QFY02, compared to the corresponding period last fiscal. Sales have jumped by more than 29% to touch Rs 1,962 m. Operating margins increased by 470 basis points to 27%, which is amongst the best in the industry. The performance of the company has been far above market expectation.

    (Rs m) 2QFY01 2QFY02 Change FY01
    Sales 1,519 1,962 29.2% 6,132
    Other Income 33 23 -31.5% 67
    Expenditure 1,179 1,431 21.3% 4,625
    Operating Profit (EBDIT) 340 531 56.3% 1,507
    Operating Profit Margin (%) 22.4% 27.1%   24.6%
    Interest (6) (11.5) 82.5% (21)
    Depreciation 35 43 21.0% 152
    Profit before Tax 344 522.3 52.0% 1,444
    Other Adjustments   -   -
    Tax 22 40 83.6% 95
    Profit after Tax/(Loss) 322 482 49.8% 1,349
    Net profit margin (%) 21.2% 24.6%   22.0%
    No. of Shares (eoy) (m) 46.8 46.8   46.8
    Diluted Earnings per share* 27.5 41.2   28.9
    P/E (at current price)   14.0   19.9

    The better than expected performance has been on the back of 130% growth in exports. The growth in exports was helped mainly due to merger with Sun Pharma Exports Ltd. However, even excluding the merger effect, net profit has grew by 35%. In the domestic formulation business, sales grew by 28%, far outperforming industry growth rates. The growth was on the back of a aggressive launch of new products. The company has launched more than 25 new products in last one quarter across various therapeutic segments.

    Sun Pharma has informed that Caraco Pharma, the US affiliate of the company expects 2 ANDA (Abbreviated New Drug Application) approvals by the end of the current calendar year. Caraco already has 3 ANDA approvals to its credit. Exports on account of this ANDA could help the Caraco Pharma to come out of red, which remains a major cause for concern.

    At Rs 575, the company trades at a P/E multiple of 14x annualised earnings for 2QFY02.



    Equitymaster requests your view! Post a comment on "Sun Pharma: Net profit leapfrogs 50%". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

    Mar 11, 2017

    Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

    Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

    Dec 12, 2016

    Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

    Sun Pharma: US Segment Shows Signs of Improvement (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Sun Pharma has announced its 1QFY17 results. The company has reported 22.7% YoY growth in sales and a growth of 266% in the net profits. Here is our analysis of the results.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts